of TNF production and protected mice challenged with LBP-dependent doses of LPS. 5 In contrast, results of another study showed that wild-type or LBP-deficient mice produced similar amounts of TNF upon exposure to LBP-dependent doses of LPS in vivo, raising doubts about the role of LBP as a mediator of LPS-induced cell activation. 6 No clear explanation is available for that discrepant observation.
CD14 IN ENDOTOXEMIA
Mice with a CD14 disrupted gene were resistant to LPSinduced toxicity in the galactosamine model. 7 Interestingly, and in contrast to observations made for LBP, CD14 -/mice were resistant to high doses of LPS (10 times the LD 100 ). 7 Antibodies to CD14 provided therapeutic benefit after in vivo exposure to endotoxin in rabbits and primates. 8, 9 A newly developed rat antibody to mouse CD14 10 protects mice sensitized with galactosamine against LPS challenge. 12
LBP IN INFECTION MODELS
Whereas LBP is a critical and detrimental component of pathophysiological events resulting from endotoxemia, its role in bacterial infections is not clearly defined ( Table 2 ). Yet, LBP and CD14 have been postulated to be prerequisites in the mechanisms involved in initiation of host defense against Gram-negative bacteria, alarming the host to the presence of minute amounts of LPS. 1 In favor of this hypothesis, LBP -/mice, while resistant to LPS, were highly susceptible to an infection caused by Salmonella typhimurium, presumably because LBPdeficient animals were unable to trigger an adequate response mediating phagocytosis and killing of the micro-organism. 5 S. typhimurium is an intracellular organism, and we have now extended this observation to extracellular Gram-negative bacteria. In particular, mice treated with neutralizing anti-LBP antibodies were highly susceptible to an intravenous infection caused by a very low inoculum (250 CFU/mouse) of virulent Klebsiella pneumoniae. 12 In contrast, anti-LBP antibodies did not improve nor decrease lethality with a higher inoculum (10 5 CFU K. pneumoniae).
CD14 IN INFECTION MODELS
The contribution of CD14 in infection models as been rarely approached ( Table 2 ). An earlier report indicated that CD14 -/mice control the dissemination of an i.p. inoculum of Escherichia coli inoculum more efficiently than wild-type mice. 7 This observation sharply contrasted with the harmful effect of absence of LBP in LBP -/mice. 5 However, recently, the intestinal mucosa of rabbits treated with a neutralizing anti-CD14 mAb exhibited a 50-fold increase in Shigella invasion and more severe injury compared with controls. 11 We have now observed 12 that a pretreatment of wild-type mice with anti-CD14 mAb strikingly increased lethality upon a challenge with 250 CFU of virulent K. pneumoniae, confirming the observation that blockade of CD14 aggravates experimental shigellosis. 11 In contrast, and similarly to observations made with anti-LBP antibodies, CD14 blockade did not improve nor decrease lethality with a higher inoculum (10 5 CFU K. pneumoniae).
Our results together with data of Wenneras et al. may appear at variance with an earlier study which showed that CD14 knock-out mice had a better survival than wild-type mice following challenge with E. coli. 7 There is no explanation for these discrepant results. In the aforementioned study, 7 CD14-deficient mice survived an intraperitoneal inoculum of 5 x 10 6 E. coli O111, that was lethal to control mice. In our studies 12 , administration of anti-LBP or anti-CD14 mAbs did not alter outcome with an inoculum of 10 5 K. pneumoniae. It is important to note that inocula higher than 10 5 CFU are LBP-and CD14-independent, as indicated by the failure to prevent TNF release from mouse whole blood stimulated with such inocula (personal observations). Studies using gene-deficient animals or animals treated with antibodies are not similar, and one possible explanation could be a change of the innate immune status of the CD14-deficient mice. Taken together, these studies indicate that LBP and CD14 are likely deleterious molecules in endotoxemia, but beneficial molecules for the control of infection. A body of data emphasizes the need for an intact mechanism of recognition of LPS leading to cytokine production in initiating host defense mechanisms against Gram-negative bacterial infections. The general mechanism is likely that proposed many years ago by Ulevitch and colleagues, 1,2 that LPS shed from Gram-negative bacteria binds to LBP and that the LPS/LBP complexes are presented to CD14 to trigger monocyte activation, leading among other mechanisms to cytokine synthesis, necessary for the host response. It has been extensively documented in vitro and in vivo that activation of myelomonocytic cells by LPS via LBP/CD14 occurs only at low doses of LPS, and that LBP or CD14 blockade does not prevent cell activation by high doses of LPS. Our data indicate a role for LBP and CD14 almost exclusively for low inocula of virulent bacteria. 12 As soon as mice were challenged with a high inoculum of bacteria, LBP-and CD14-independent mechanisms occured, either because LPS was present in too large a concentration, or because bacterial products other than LPS triggered monocyte activation. Yet, despite triggering host response, death occurred rapidly. This illustrates the point that many experimental models of sepsis performed in the past with high inocula of bacteria, were LBP-and CD14-independent models of LPS intoxication rather than true models of infection. This also stresses the need for critical evaluation of novel therapeutic approaches for the management of patients with severe sepsis or shock.
